Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of retinal gene therapy in choroideremia and X-linked retinitis pigmentosa
NL-OMON54647Phase 3Completed
- Sponsor
- Nightstar Therapeutics
- Start
- Jan 2022
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label trial of timrepigene emparvovec and cotoretigene toliparvovec in choroideremia and retinitis pigmentosa (RP) (3 arms), sponsored by Nightstar Therapeutics. Primary endpoint: Safety. Started Jan 2022; status: completed.
02
Drugs
timrepigene emparvoveccotoretigene toliparvovec
03
Conditions
choroideremiaretinitis pigmentosa (RP)
Beyond the preview
Go deeper on NL-OMON54647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54647.